We suggest that tACS protocols be based on functional brain mechanisms and appropriate control experiments, including active sham and condition blinding. Electrophysiological measurements are ...

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that Ingrezza (valbenazine) provided meaningful and sustained benefits for patients ...

It is important for clinicians to understand the causes and symptoms of tardive dyskinesia to avoid common misdiagnoses and ensure effective management.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $1 EPS, expectations were ...

Q4 revenue was $627.7 million, slightly below the $629 million estimate. Ingrezza remains the main revenue driver, with a 23% increase in quarterly sales to $615 million. Neurocrine Biosciences ...

School of Materials Science and Engineering, Peking University,Beijing,100871,China School of Materials Science and Engineering, Peking University,Beijing,100871,China Beijing Key Laboratory of Theory ...

School of Materials Science and Engineering, Peking University, Beijing 100871, P. R. China Beijing National Laboratory for Molecular Sciences, National Biomedical Imaging Center, College of Chemistry ...

As with other drugs, Ingrezza (valbenazine) can cause side effects, such as drowsiness and parkinsonism. If you are unable to tolerate Ingrezza’s side effects, talk with your doctor or ...

In order to provide an overview of the recently uncovered cellular and molecular mechanism during oocyte maturation, especially epigenetic modification, the progress of the regulatory network of ...